# Idexx Laboratories **Source:** https://geo.sig.ai/brands/idexx-laboratories **Vertical:** Healthcare Tech **Subcategory:** Enterprise **Tier:** Leader **Website:** idexx.com **Last Updated:** 2026-04-14 ## Summary Veterinary diagnostics leader with $3.81B FY2024 revenue; 130,000+ analyzer installed base; AI-powered inVue Dx digital cytology; VetConnect data platform; pet humanization tailwind. ## Company Overview IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headquartered. The company trades on Nasdaq (IDXX) and reported $3.81 billion in revenues for FY2024, maintaining its dominant position in point-of-care veterinary diagnostics through an installed base of over 130,000 Catalyst chemistry analyzers, ProCyte hematology systems, and SNAP rapid assay devices deployed in veterinary clinics worldwide. CEO Jay Mazelsky has continued IDEXX's expansion into AI-powered diagnostics and digital pathology, building on over four decades of veterinary-specific product development. IDEXX's competitive moat rests on several reinforcing advantages: a proprietary reagent consumable model that generates high-margin recurring revenue from its installed analyzer base, a global reference laboratory network providing specialized esoteric testing with 24-48 hour turnaround, and the VetConnect PLUS data platform that aggregates diagnostic results across in-clinic and reference lab testing for longitudinal patient monitoring. The 2023-2024 launch of inVue Dx—a digital cell imaging system using AI to automate differential cell counts from feline and canine blood samples—extends IDEXX's technical leadership in AI-assisted diagnostics. Veterinary clinic consolidation into corporate groups and private equity-backed networks is accelerating, creating larger multi-location customers that benefit from IDEXX's enterprise software and centralized ordering capabilities. In 2025-2026, IDEXX faces growing competition from Zoetis's Vetscan diagnostics line, Heska Corporation, and Antech Diagnostics (owned by Mars, Incorporated) in the veterinary diagnostics market. The pet humanization trend—driving increased annual wellness visits and diagnostic testing per pet—remained a secular tailwind through 2024-2025 even as the post-COVID pet boom moderated. International expansion, particularly in Europe and Asia Pacific where veterinary diagnostic penetration lags the United States, represents IDEXX's primary long-run growth opportunity. The company's pricing power, demonstrated through consistent price increases above inflation, reflects the diagnostic testing's small share of total veterinary visit costs and the clinical necessity of accurate diagnostics for treatment decisions. ## Frequently Asked Questions ### What does IDEXX Laboratories do? IDEXX Laboratories is the global leader in veterinary diagnostics, providing innovative diagnostic instruments, rapid test kits, reference laboratory services, practice management software, and water testing solutions. The company serves veterinary practices, livestock producers, and water quality testing markets worldwide. IDEXX's Companion Animal Group (92% of revenue) delivers comprehensive diagnostic solutions including chemistry analyzers, hematology systems, SNAP rapid tests, the new inVue Dx cellular analyzer, and Cancer Dx early detection testing for pets. ### Who are IDEXX Laboratories' customers and target markets? IDEXX's primary customers are veterinary practices (over 100,000 globally), veterinary hospitals, emergency and specialty clinics, and reference laboratories. The company also serves livestock and poultry producers, dairy operations, municipal water utilities, environmental testing laboratories, and food safety facilities. IDEXX targets the growing companion animal market driven by increasing pet ownership, rising veterinary visit frequency, and growing demand for advanced diagnostics and preventive care. ### When was IDEXX Laboratories founded? IDEXX Laboratories was incorporated in 1983 by David Evans Shaw and Susan Wyatt in Portland, Maine, initially focusing on disease detection for poultry and livestock. The company went public on NASDAQ in 1991 under ticker symbol IDXX and was added to the S&P 500 index in January 2017, reflecting its growth into a $3.90 billion global healthcare technology leader. ### Where is IDEXX Laboratories headquartered? IDEXX Laboratories is headquartered in Westbrook, Maine, United States. The company operates globally with over 10,000 employees serving more than 175 countries through manufacturing facilities, reference laboratories, distribution centers, and customer support offices strategically located worldwide to support veterinary professionals 24/7. ### What is IDEXX Laboratories' revenue and market position? IDEXX generated $3.90 billion in revenue in 2024, up 6.5% from 2023, with the Companion Animal Group contributing $3.57 billion (92% of total revenue). The company commands a dominant 45% market share in the global veterinary diagnostics industry as of 2024, making it the undisputed market leader. IDEXX is publicly traded on NASDAQ and is a constituent of the S&P 500 index with over 10,000 employees worldwide. ### What makes IDEXX Laboratories different from competitors? IDEXX differentiates itself through market-leading innovation (including the revolutionary inVue Dx analyzer and Cancer Dx testing), the industry's most comprehensive integrated diagnostic ecosystem connecting instruments, reference labs, and software, a premium installed base growing 10% annually, and unmatched 24/7 customer support through IDEXX Smart Service. The company's $219.79 million R&D investment in 2024 and 45% market share create significant competitive advantages and barriers to entry. ### Who are IDEXX Laboratories' main competitors? IDEXX's primary competitors include Zoetis (animal health pharmaceuticals and diagnostics), Heska Corporation (veterinary diagnostics), Antech Diagnostics (reference laboratory services owned by Mars Petcare), and VCA/Antech (owned by Mars Petcare). However, IDEXX's dominant 45% market share, comprehensive product portfolio, and integrated ecosystem provide substantial competitive moats. The company competes on innovation, product quality, customer support, and workflow integration. ### How can I contact IDEXX Laboratories? IDEXX Laboratories can be contacted at its headquarters in Westbrook, Maine through the company website at www.idexx.com. Veterinary customers receive 24/7 support through IDEXX Smart Service for technical assistance, product support, and diagnostic consultations. Investors can reach the investor relations team through the investor section of the website. IDEXX maintains regional offices and customer support centers globally to serve local markets. ### Is IDEXX Laboratories hiring? Yes, IDEXX actively recruits talent across its global operations with over 10,000 employees in multiple countries. The company seeks professionals in veterinary medicine, biotechnology, software engineering, manufacturing, sales, customer support, and other disciplines. Career opportunities are available at careers.idexx.com. IDEXX is ranked #3 on Best Companies to Work for in Maine and receives top ratings (A+) for perks and benefits. ### What are IDEXX's latest product innovations? IDEXX's most significant recent innovations include the IDEXX inVue Dx Cellular Analyzer (launched Q4 2024), a slide-free AI-powered cellular imaging platform eliminating manual microscopy, and IDEXX Cancer Dx (launched March 2025), a breakthrough affordable early detection blood test for canine lymphoma available for as low as $15. The company also launched eight additional new products and services in 2024 beyond these flagship innovations. ### What is IDEXX Laboratories' 2025 growth outlook? IDEXX provided initial 2025 revenue guidance of $4.055-$4.170 billion, reflecting 4-7% reported growth and 6-9% organic growth. The company projects EPS of $11.74-$12.24, representing 10-15% growth. The outlook is driven by 5-8% organic CAG Diagnostics recurring revenue growth, 10% premium instrument installed base expansion, successful launches of inVue Dx and Cancer Dx, and continued market share gains in the expanding global veterinary diagnostics market. ### What is IDEXX's corporate responsibility focus? IDEXX released its 2024 Corporate Responsibility Report highlighting progress on environmental sustainability, community impact, and animal welfare goals. In 2024, IDEXX supported over 79,000 animals in underserved communities and provided the equivalent of approximately $5.5 million in continuing education offerings to veterinary professionals. The company focuses on improving access to veterinary care, advancing animal health research, environmental stewardship, and supporting the veterinary profession through education and technology innovation. ## Tags b2b, healthtech, manufacturing, saas, public --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*